Evidence map›Paper›PMID 42473157›Full record

ArticleJournal of proteome research2026

Improved Protein Identification in Shotgun Proteomics with a Group-Level Extension of the LPGF Model.

Gorka Prieto, Jesús Vázquez

Abstract read
In one paragraph

Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Gorka PrietoDepartment of Communications Engineering, University of the Basque Country (UPV/EHU), 48013Bilbao, Spain.ORCID 0000-0002-6433-8452
Jesús VázquezCardiovascular Proteomics Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029Madrid, Spain.

Funding

Comunidad de Madrid S2022/BMD-7333-CMEuropean Regional Development Fund NAHezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza IT1473-22'la Caixa' Foundation LCF/PR/HR22/52420019Ministerio de Ciencia, Innovaci?n y Universidades PID2024-155650NB-I00
6 · The paper itself

Abstract

Shotgun proteomics relies on robust statistical methods to increase the confidence of the protein identifications. Previously, we introduced LPGF, a protein probability model based on unique peptides. In this study, we extend LPGF to protein groups that share peptides by considering only peptides that are unique to each group. This strategy preserves the principle of unique evidence while enabling the probability estimation at the protein-group level. Applying our method to three tissues from the Human Proteome Map (HPM), we evaluated the gain in protein identifications obtained with group-unique peptides compared to those obtained using only protein-unique peptides and different scores. The accuracy of false discovery rate (FDR) estimation was further validated using a standard data set for protein inference based on human Protein Epitope Signature Tags (PrESTs), as well as through an entrapment experiment using the substantially larger HPM data set. To facilitate adoption, we developed an R package (b10prot) that integrates the full workflow, including protein-level and group-level LPGF score computation and protein grouping via an R port of our previous tool PAnalyzer. Our results demonstrate that extending LPGF to protein groups increases sensitivity while maintaining robust FDR control, thus providing the proteomics community with a practical framework for more comprehensive protein identification.

Indexed as

ProteinsProteomeProteomicsHumansPeptidesSoftwareTandem Mass SpectrometryPeptidesProteinsProteomeFDRprotein identificationproteomicstarget-decoy approach

Identifiers

PMID42473157
PMCPMC13459553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.